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Polycystic ovarian syndrome (PCOS) is frequently characterized by obesity and metabolic diseases including hypertension, insulin
resistance, and diabetes in adulthood, all leading to an increased risk of atherosclerosis. The present study aimed to evaluate serum
and production of inﬂammatory markers in adolescent Sardinian PCOS. On the basis of HOMA ﬁndings, patients were divided
into noninsulin resistant (NIR) and insulin resistant (IR), and were weight- and age-matched with healthy girls. Inﬂammatory
cytokines(TNF-α,IL-6,Il-10,TGF-β)andlipokines(leptin,adiponectin),thereactanths-CRP,andinvitroinﬂammatorylympho-
monocyte response to microbial stimulus were evaluated. In healthy and PCOS subjects, leptin and hs-CRP were correlated with
BMI,whereasadiponectinwassigniﬁcantlyreducedinallPCOSgroups.Althoughcytokinesweresimilarinallgroups,Interleukin-
6 (IL-6) was signiﬁcantly higher in IR PCOS. Moreover, in the latter group lipopolysaccharide-activated monocytes secreted
signiﬁcantly higher levels of IL-6 compared to NIR and control subjects. To conclude, IR PCOS displayed increased IL-6 serum
levels and higher secretion in LPS-activated monocytes, whilst revealing no diﬀerences for other inﬂammatory cytokines. These
results suggest that in PCOS patients an altered immune response to inﬂammatory stimuli is present in IR, likely contributing
towards determining onset of a low grade inﬂammation.
1.Introduction
Polycystic Ovarian Syndrome (PCOS) is a complex disease
characterizedbyhyperandrogenismandchronicanovulation
[1]. The detection of traditional cardiovascular (CV) risk
factors, that is, insulin resistance, diabetes, visceral obesity
[2–6], and a state of low-grade inﬂammation [7–10], places
these patients at a signiﬁcantly higher risk for development
of symptomatic atherosclerotic CV diseases. The presence
of a cluster of metabolic and inﬂammatory factors has
often been described in obese PCOS compared with age-
and weight-matched controls. Higher serum levels of hs-
CRP [11], IL-6 [12], and leptin have been reported, the
latterbeingaproinﬂammatorymoleculemainlyproducedby
adipose tissue [13–15]. The latter alterations were all related
to BMI, mainly increased visceral adipose tissue, frequently
observed in these patients and which in turn correlates
with insulin resistance [8, 16]. Conversely, adiponectin,
an anti-inﬂammatory lipokine was found to be decreased
in all PCOS patients [17, 18]. Although the majority of
related articles focus on CV risk in adult PCOS, with
this aspect currently being studied also in young PCOS
patients, the various inﬂammatory markers are frequently
investigated in separate studies [2, 9, 19, 20]. The aim
of the present paper was to evaluate the most frequently
investigated inﬂammatory cytokines during the early stages
of reproductive life in a Sardinian PCOS population, both
with or without insulin resistance. Indeed, the study eval-
uated cytokine production following microbial and mito-
genic stimuli in lymphomonocytes from healthy and PCOS2 Mediators of Inﬂammation
subjects, as these molecules are primarily of immunological
origin.
2.SubjectsandMethods
2.1. Recruitment and Characterization of Study Participants.
From January 2007, 44 young girls aged 15–23 aﬀected by
PCOS were recruited at the Adolescent Centre for Gyneco-
logical Diseases, Department of Obstetrics and Gynecology,
“San Giovanni di Dio” Hospital, University of Cagliari.
The diagnosis of PCOS was made according to Rotterdam
criteria [21] in the presence of at least two of the following:
(1) oligomenorrhea (40 subjects) and/or anovulation (4 sub-
jects), (2) hyperandrogenism (clinical and/or biochemical);
(3) polycystic ovaries with the exclusion of other etiologies.
All subjects had previously been screened to exclude other
causes of hyperandrogenism, such as androgen-secreting
tumors and congenital adrenal hyperplasia (tested by evalua-
tion of 17-4 hydroxyprogesterone), and for euthyroid status,
hyperprolactinemia, diabetes, hypertension, and other car-
diovascular diseases. Over the three months preceding the
studynosubjecthadbeenonhormonalcontraceptives,other
medications or diet which could have aﬀected lipid proﬁle,
carbohydrate metabolism, and insulin levels. No subject
smoked or consumed alcohol. All study participants were
asked to refrain from intense physical activity.
Fifty-ﬁve healthy young female volunteers with regular
menstrual cycles, matched for BMI and with no clinical
or biochemical signs of hyperandrogenism and ultrasound
exclusion of PCO, took part as a control group. Subjects
were all free from medication at the time of the study. No
participants manifested or referred recent clinical infections.
Investigationswereconductedbetweendays5and8fromthe
lastmenstrualcycle.Thelatterwasinducedin4patientswith
amenorrhoea by administering progestinic drugs.
2.2. Measures and Analysis. Hormonal study (after 12
hours fasting) included a baseline plasma determination
of androstenedione (A), testosterone (T), and prolactin
(PRL). LH, FSH, estradiol (E2), dehydroepiandrosterone-
sulphate (DHEAS); 17-hydroxyprogesterone (17-OHP), and
sex hormone binding globulin (SHBG) levels were also
assayed but are not reported in the present paper. Plasma
samples for hormone determination were maintained at
−20◦C until assay. All hormones were measured by RIA
methods using commercial kits (Radim, Pomezia, and Ares
Serono, Milan, Italy). Samples were immediately processed
in a refrigerated centrifuge, and the sera obtained stored at
−20◦C until assay. The intra-assay and interassay coeﬃcients
of variation obtained were <9% for all hormones. Blood
samples for insulin (Diagnostic systems laboratories, INC.
(DSL), Webster, TX) and glycemia (glucosidase method,
Beckman glucose analyzer, Fullertonn Ca) were measured
during a 75g oral glucose tolerance test (OGTT), at 0, 30, 60,
90, 120, and 180min from glucose load. A normal glycemic
response to OGTT was deﬁned according to the criteria of
the National Diabetes Data Group [22]. Insulin and glucose
responses were expressed as area under the curve (AUC-
180), calculated according to the trapezoidal rule [23]. The
homeostatic index of IR (HOMA) was estimated considering
fasting glucose (mmol/L) and insulin (μU/mL) divided by
a constant (Io × Go/22.5) [24]. To identify the prevalence
of IR in young PCOS patients, HOMA values obtained
from control group were pooled to establish upper control
values using the mean +2 standard deviation as previously
described [19, 24, 25]. On the basis of 95% conﬁdence limits,
HOMA test was considered normal when lower than 65.6.
Body mass index (BMI) was calculated according to the
following formula: weight in kilograms/(height in meters) 2.
Toascertainwhethermetabolicstatecouldbeassociatedwith
a peculiar inﬂammatory pattern, patients were divided into
two groups according to HOMA status: nonresistant (NIR)
and insulin resistant (IR). Results were further evaluated
considering all PCOS patients as a single group.
2.3. Cytokine Assay. A serum sample from each participant
was stored at −80◦C for determination of IL-1β,I L - 6 ,T N F -
α, Il-10, TGF-β, hs-CRP, leptin, and adiponectin. Cytokines
were assessed using a sandwich ELISA test (Biosource,
Nivelles, Belgium) as reported previously [26]. Absorbance
at 450nm for all cytokines was measured with a model 680
microplate reader (Bio-rad, Hercules, CA). A standard curve
was prepared by plotting absorbance value of the standard
cytokine versus the corresponding concentration (pg/mL or
ng/mL). The range of the assay was 7.8–500pg/mL for IL-
1β, 0.16–10pg/mL for IL-6, 15.6–1000pg/mL for TNF-α,
31.2–2000pg/mL for IL-10, 15.6–1000pg/mL for leptin, 0.5–
32ng/mL for adiponectin, and 78–5000pg/mL for CRP. The
range of assay for cytokine cultures was 7.8–1000pg/mL for
IL-1β, 7.8–1000pg/mL for IL-6, 7.8–1000pg/mL for TNF-α,
31.2–2000pg/mL for IL-10, and 62.5–4000pg/mL TGF-β.I n
some experiments the secretion of monocyte cytokines into
medium was evaluated using samples obtained from several
patients and controls. Cells were removed by centrifugation
of 400g for 10min and supernatants frozen at −20◦C until
assay. Cell protein content was measured by Bradford assay
[27].
2.4. Cell Isolation and Culture. Informed consent for in
vitro studies was obtained from 8 IR, 5 NIR, and 8
control subjects. Lymphomonocytes were separated from
a 25mL of whole heparinized blood. Each blood sample
was diluted twice with RPMI 1640 before centrifugation
on Ficoll-Hipaque (density 1.077; Sigma Chemical Co.) at
800g for 20min at room temperature. The interphase band,
containing the mononuclear cells, was collected and cells
puriﬁed as previously described [28]. Purity for platelets, red
cells, and granulocytes was checked. Viability, monitored by
trypan blue dye exclusion, exceeded 98% in all experiments.
Lymphomononuclear cells, at a density of 3 × 106/mL,
were cultured in RPMI 1640 medium supplemented with
2% heat-inactivated human AB serum, penicillin 100U/mL,
streptomycin 100mg/mL and 2mM L-glutamine, and were
allowed to adhere at 37◦Ci na5 %C O 2 atmosphere for
2 hours. After removal of nonadherent cells, 80–90% ofMediators of Inﬂammation 3
the observed cells was represented by monocytes, as assessed
by anti-CD-14b staining and ﬂow cytometric analysis. Cells
were washed twice with prewarmed medium and cultured
with RPMI-1640 supplemented with heat inactivated 10%
AB plasma. To avoid the eﬀect of unknown inﬂammatory
factors present in plasma from patients and/or volunteers,
commercially obtained AB serum (Sigma-Aldrich, Milan,
Italy) was used. Cells were subsequently treated according to
experimental requirements as described later in this section.
Adherent monocytes were activated with LPS (serotype
026:B26, 100ng/mL per 24).
On completion of experiments medium supernatants
werestoredat −70◦Candcytokinesmeasuredconcomitantly
to avoid variations in assay conditions. In some experiments,
the suspended lymphocytes were lectin-stimulated (PHA
10ng) and utilized to evaluate proliferative and inﬂamma-
tory response. An aliquot of cells was hydrolyzed with NaOH
for protein determination.
2.5. Cholesterol Esteriﬁcation. Adherent cells were incubated
for 4 hours in medium containing [14C]-oleate bound to
bovine serum albumin (BSA). To prepare the oleate-BSA
complex, 3.7MBq of [14C]-oleic acid in ethanol (Dupont,
NEN speciﬁc activity 2.035GBq/mmol) was mixed with
1.4mg of KOH and the ethanol evaporated. PBS (1.5mL)
withoutCa2+ andMg+ containing4.24mgofBSA(fattyacid
free, Sigma) was added and the mixture shaken vigorously.
This solution was added to each well at a ﬁnal concentration
of 74KBq/mL. After incubation, cells were washed with ice-
cold PBS and lipids extracted with acetone. Neutral lipids
were separated by TLC as previously described [28, 29]a n d
incorporation of [14C]-oleate into cholesterol esters was
measured. An aliquot of cell hydrolysate was processed for
protein content.
2.6. Statistical Analysis. Data were expressed as mean ±
SEM, and diﬀerences between groups were evaluated by
the Student’s t-test. For systemic markers of inﬂammation,
owing to the prominent skewness of distributions, data
were expressed as median, interquartile and min-max ranges
and diﬀerences between groups were evaluated using the
nonparametric Mann-Whitney U test. Nonparametric cor-
relations between variables were evaluated by the Kendall tau
correlation coeﬃcient.
3. Results
3.1. Anthropometric and Hormonal Characteristics in PCOS
Patients and Controls. The study was approved by the Ethical
Committee of the University of Cagliari. Written informed
consent was obtained from all subjects and/or their parents
or legal guardian before participating in the study. In line
with the presence of peripheral insulin resistance (HOMA
> 65,6), PCOS subjects were divided into 2 subgroups:
19 insulin-resistant (IR) and 25 noninsulin-resistant (NIR)
subjects. As shown in Table 1, BMI, AUC-I 180, and HOMA-
7,16 were signiﬁcantly higher in IR PCOS. As expected,
androgen and testosterone plasma levels were increased in
all PCOS patients (Table 2). Menstrual irregularities were
present in 90% of PCOS patients. Glycemia was normal in
all subjects (data not shown). No signiﬁcant diﬀerences were
found in plasma lipids (data not shown). In accordance with
the four criteria established by Cook (30), no subjects were
aﬀected by metabolic syndrome.
3.2. Systemic Markers of Inﬂammation. As shown in
Figure 1(a) leptin levels were higher in all PCOS groups,
the higher values being found in IR patients (median:
16.30pg/mL; min-max range: 3.6–120.00; P < .05) on com-
parison of single groups to controls (median: 10.30pg/mL;
min-max range: 4.00–59.81), thus displaying a trend similar
to that observed for BMI (Figure 1(b)). On the contrary,
adiponectin (Figure 1(c)) was signiﬁcantly decreased in all
PCOS groups: IR (median: 11.40ng/mL; min-max range:
6.50–24.80; P < .05), NIR (median: 14.15ng/mL; min-max
range: 5.70–34.98; P < .05), compared to control values
(median: 15.80ng/mL; min-max range: 4.80–37.10). CRP
values, although revealing a trend similar to leptin and
BMI, were signiﬁcantly increased in IR (median 555pg/mL,
min-max range: 54.35–1668) compared to NIR (median
189.67pg, min-max: 41.2–943) and control (median:
139,6pg min-max range: 41,2–1772) groups (Figure 1(d)).
No variation in TNF-α (Figure 2(a)) was observed in any
group, and similar observations were made for IL-1β, Il-10,
and TGF-β (data not shown).
However, IL-6 (Figure 2(b)) was signiﬁcantly increased
in all groups, when compared to controls (median:
0.28pg/mL; min-max range: 0.13–12), with a peak in IR
(median:2.79pg/mL;min-maxrange:0.56–12.00;P < .001).
When considering BMI and leptin (r = 0.6071; P < .001), as
well as BMI and adiponectin (r = −0.3387; P > .002), both a
positive and a negative correlation, respectively, was found in
all subjects, independent of PCOS status. A correlation was
detected between BMI and IL-6 in the control group (r2 =
0,64) but the range of IL-6 values was deﬁnitely lower than
that observed in both NIR and IR groups. In addition, in
both PCOS groups the correlation was very low (r2 = 0.004
and 0.16 NIR and IR, resp.).
3.3. Production of Inﬂammatory Molecules in Lymphomono-
cytes. Inﬂammatory response was evaluated in lymphocytes
and monocytes challenged with microbial stimulus. TNF-
α and Il-β, as well as the anti-inﬂammatory cytokine Il-10
and TGF-β secretion in 24-hour LPS-activated monocytes,
were similar in PCOS and control groups (data not shown).
On the contrary, IL-6 production was remarkably and
signiﬁcantly higher in all LPS-treated monocytes from IR
when compared to NIR and controls (Figure 3).
Inﬂammatory cytokines and proliferative response eval-
uated in lymphocytes from the same subjects did not reveal
signiﬁcant diﬀerences between groups (data not shown).
3.4. Cholesterol Esteriﬁcation Did Not Vary in LPS-Treated
Monocytes. As shown in Figure 4, LPS did not modify the
rate of cholesterol esteriﬁcation, the pathway leading to foam4 Mediators of Inﬂammation


























































































Figure 1: Leptin, BMI, adiponectin, and CRP in PCOS and control girls in controls (c), noninsulin resistant (NIR), and (IR) girls. Due to
the strongly asymmetric distribution of data, the graph shows the median(middle bar), interquartile ranges (boxes), and min-max ranges
(end bars). P < .005 by Mann-Whitney U test.
Table 1: Anthropometric and metabolic characteristics of the study population (mean ± SD).
Controls PCOS IR NIR
N 55 44 19 25
Age (yr) 18.1 ± 3.1 19.1 ± 3.8 19.2 ± 3.8 19.1 ± 3.9
BMI (kg/m2) 24.8 ± 4.7∗ 25.1 ± 5.9 27.1 ± 7.2 23.2 ± 4.7
Oligomenorrhea % 0 90% (40 subjects)
Amenorrhea % 0 3% (4 subjects)
Waist (cm) (M ± ES) 81.2 ± 12.0 82.7 ± 16.1 88.6 ± 16.9 76.8 ± 15.4
Hips (cm) (M ± ES) 105.0 ± 10.0 102.6 ± 12.3 108.0 ± 12,9 97.3 ± 11.7
AUC-I 180 13,133 ± 7,115∗ 23,599 ± 9,998 24,961 ± 11,133 22,238 ± 8,864
HOMA- 7,16 46.7± 13.3∗ 65.2 ± 12.6 84.2 ± 14.3 46.8 ± 11.0
∗P < .05 versus IR patients.Mediators of Inﬂammation 5
Table 2: Hormonal characteristics of the study population (mean ± SD).
Controls PCOS IR NIR
n 55 44 19 25
T (nmol/L) (M ± ES) 0.4 ± 0.2∗ 0.6 ± 0.4 0.6 ± 0.4 0.7 ± 0.4
A (nmol/L) (M ± ES) 1.7 ± 0.8∗ 2.3 ± 1.0 2.2 ± 0.9 2.3 ± 1.1
PRL (ng/mL) 25.4 ± 8.1 23.1 ± 13.0 20.3 ± 10.6 26.0 ± 15.5
LH (IU/L) (M ± ES) 3.7 ± 1.5 3.9 ± 2.5 4.0 ± 2.1 3.9 ± 2.8
FSH (IU/L) (M ± ES) 6.1 ± 2.8 5.4 ± 1.6 5.7 ± 1.4 5.2 ± 1.8
E2 (pmol/L) (M ± ES) 17.6 ± 25.4 27.3 ± 26.5 22.6 ± 10.6 30.9 ± 33.7
DHEAS (μmol/L) (M ± ES) 1.5 ± 0.6 2.2 ± 1.3 2.2 ± 1.3 2.2 ± 1.3
17OHP (ng/mL) (M ± ES) 1.2 ± 0.6 1.4 ± 1.8 1.1 ± 0.4 1.7 ± 2.4
SHBG (nmol/L) (M ± ES) 74.4 ± 34.7 66.6 ± 37.9 45.7 ± 24.7 81.4 ± 39.0
∗P < .05 versus IR and NIR.






































Figure 2: TNF-α and IL-6 levels in PCOS and control girls. Due to the strongly asymmetric distribution of data, the graph shows the median
(middle bar), interquartile ranges (boxes), and min-max ranges (end bars). P < .005 by Mann-Whitney U test.
cell formation, hallmark of atherosclerosis, either in PCOS
patients or controls.
4. Discussion
The present study demonstrates that the presence of a cluster
of metabolic and inﬂammatory factors in insulin resistant
PCOS girls is accompanied by an altered immune response
to microbial stimulus, contributing to higher levels of serum
IL-6. PCOS patients, frequently aﬀected by visceral obesity
and insulin-resistance [30, 31], feature an increased risk
of developing atherosclerotic vascular disease later in life
[2–7, 32–34]. A large body of reports published to date
has focused on the evaluation in middle-aged females of
metabolic, hormonal, and inﬂammatory factors accounting
for low-grade inﬂammation leading to atherosclerosis [8–10,
35–40].AlthoughthemajorityofrelatedarticlesfocusonCV
risk in adult PCOS, a condition of low-grade inﬂammation
has also been described in adolescent girls [2, 20, 30, 40,

































control girls. Each value represents mean ± SEM of 8 separated
experiments. ∗LPS-activated monocytes from PCOS versus LPS-






















































Figure 4: Cholesterol esteriﬁcation in LPS-activated monocytes
from PCOS and control girls. Each value represents mean ± SEM
of 8 separated experiments.
at times exceeded that obtained in controls, although no
subjectsexamineddevelopeddiabetes.Accordingly,BMIand
the prevalence of metabolic syndrome in the Italian female
populationhasalreadybeenreportedtobelowerthanﬁgures
obtained for their American counterpart [42, 43].
In the present study a cluster of molecules implicated
in the onset of low-grade inﬂammation of the arterial wall
was detected largely in adolescent girls developing insulin
resistance. As reported [17, 18, 44], anti-inﬂammatory
adiponectin alone was signiﬁcantly lower in all PCOS
patients examined, irrespective of BMI and insulin
resistance, whereas in PCOS and normal healthy adults
[11, 13, 14, 35], hs-CRP and leptin were positively correlated
with BMI. The above molecules are likely related to the
increased visceral adipose tissue often reported in the
literature [8, 18, 45]. The increase revealed in waist to hip
(W/H) ratio in PCOS subjects is a common observation
[46–48] and is suggestive of a correlation with visceral
adipose tissue, irrespective of BMI.
Since visceral adipose tissue is associated with an
increased production of a large number of functional
molecules, it may be implicated, at least in part, in both
insulin resistance and low-grade inﬂammation. A signiﬁcant
increase in serum proinﬂammatory cytokines was observed
only for IL-6, featuring higher levels in all IR PCOS,
independent of BMI. Although described by others [49]n o
increase of serum levels and production of TNF alfa was
detected in our population. It is well acknowledged that
IL-6 has been implicated in cardiovascular atherosclerotic
risk, dyslipidemia, and hypertension. Moreover, it is a potent
inducer of hepatic CRP [50], a molecule displaying increased
levels in patients with severe atherosclerosis and following
acute clinical events (myocardial infarction and cerebral
ictus). It is a well-established fact that, in addition to visceral
adipose tissue, activated lymphomonocytes produce large
amounts of cytokines (for review see [51]). Investigations
were thus undertaken to evaluate cytokine production in
the latter cells, strongly involved in atherosclerotic plaque
formation. Indeed, in the presence of an appropriate stim-
ulus, these are the ﬁrst cells recruited in the arterial wall [52].
Of all the pro- and anti-inﬂammatory cytokines evaluated,
IL-6 production alone proved to be invariably higher in LPS-
activated monocytes from IR subjects, whereas only 1 out of
5 NIR produced IL-6 comparably to IR cells.
The results obtained suggest that an altered milieu due
to insulin resistance may inﬂuence production of IL-6 in
these cells. It may of course be argued that culture conditions
do not reproduce the “in vivo” environment, however, in
an attempt to better resemble ex vivo conditions, following
separation, cells were immediately cultured in presence of
LPS for 24 hours. Nevertheless, neither the susceptibility
of monocytes to evolve into foam cells, nor mitogenic and
inﬂammatory response to lectin in lymphocytes diﬀered
between IR and NIR PCOS and controls. Nevertheless, it
remains to be seen whether potential diﬀerences may be
manifestedlaterinlifeoronthemanifestationofametabolic
disease. Accordingly, an abnormal production of TNF alfa
has been described in monocytes from diabetic PCOS [50].
To conclude, the results obtained in this study strongly
suggest that hormonal and metabolic factors in young PCOS
subjects are strongly associated with insulin resistance, and
may concur to determine a condition of low-grade inﬂam-
mation eliciting an overproduction of IL-6 monocytes in IR
PCOS subjects following microbial inﬂammatory stimulus.
This aspect should be carefully taken into consideration
in view of recent evidence implicating infections as new
atherosclerotic risk factors [53, 54]. Should proof of the
latter be provided, further studies should be undertaken to
investigate immune response in PCOS girls, particularly in
view of the number of diﬀerent microbial agents to which
an individual is exposed during his or her lifetime. Finally,
the results obtained suggest that high IL-6 in young PCOS
subjects may also represent a signal of altered immune
response that may enhance the identiﬁcation of subjects
featuring an increased risk of cardiovascular disease later in
life.
Funding
The study was funded by Fondazione Banco di Sardegna,
Regione Autonoma della Sardegna and Nutrisearch Srl
(Italy).
Conﬂict of Interests
There is no conﬂict of interest that could be perceived as
prejudicing the impartiality of the research reported.
Abbreviations
AUC-180: Area under the curve for glucose above
180mg/dL
BMI: Body mass index
HOMA-IR: Homeostasis model assessment of
insulin resistanceMediators of Inﬂammation 7
hs-CRP: Highly sensitive Creactive protein
PCOS: Polycystic ovary syndrome.
Acknowledgments
The Authors thank Ms. Anne Farmer for editing of the
English language, Dr. Maria Collu for critical review of the
paper, Professor Giacomo Diaz for statistical calculations,
and Mrs. Anna Saba for technical assistance. The study
was funded by Fondazione Banco di Sardegna, Regione
Autonoma della Sardegna and Nutrisearch Srl (Italy).
References
[1] S. Franks, “Polycystic ovary syndrome: a changing perspec-
tive,” Clinical Endocrinology, vol. 31, no. 1, pp. 87–120, 1989.
[2] R.Shroﬀ,A.Kerchner,M.Maifeld,E.J.R.VanBeek,D.Jagasia,
and A. Dokras, “Young obese women with polycystic ovary
syndrome have evidence of early coronary atherosclerosis,”
Journal of Clinical Endocrinology and Metabolism, vol. 92, no.
12, pp. 4609–4614, 2007.
[ 3 ]E .O .T a l b o t t ,D .S .G u z i c k ,K .S u t t o n - T y r r e l le ta l . ,“ E v i -
dence for association between polycystic ovary syndrome and
premature carotid atherosclerosis in middle-aged women,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no.
11, pp. 2414–2421, 2000.
[4] R. C. Christian, D. A. Dumesic, T. Behrenbeck, A. L. Oberg, P.
F. Sheedy, and L. A. Fitzpatrick, “Prevalence and predictors of
coronary artery calciﬁcation in women with polycystic ovary
syndrome,” Journal of Clinical Endocrinology and Metabolism,
vol. 88, no. 6, pp. 2562–2568, 2003.
[5] F. Orio Jr., S. Palomba, L. Spinelli et al., “The cardiovascu-
lar risk of young women with polycystic ovary syndrome:
an observational, analytical, prospective case-control study,”
Journal of Clinical Endocrinology and Metabolism, vol. 89, no.
8, pp. 3696–3701, 2004.
[ 6 ] F .G i a l l a u r i a ,F .O r i o ,S .P a l o m b a ,G .L o m b a r d i ,A .C o l a o ,a n d
C. Vigorito, “Cardiovascular risk in women with polycystic
ovary syndrome,” Journal of Cardiovascular Medicine, vol. 9,
no. 10, pp. 987–992, 2008.
[7] E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine
organ,” Journal of Clinical Endocrinology and Metabolism, vol.
89, no. 6, pp. 2548–2556, 2004.
[ 8 ] J .J .P u d e r ,S .V a r g a ,M .K r a e n z l i n ,C .D eG e y t e r ,U .K e l l e r ,a n d
B. M¨ uller, “Central fat excess in polycystic ovary syndrome:
relation to low-grade inﬂammation and insulin resistance,”
Journal of Clinical Endocrinology and Metabolism, vol. 90, no.
11, pp. 6014–6021, 2005.
[ 9 ]I .T a r k u n ,B .C .A r s l a n ,Z .C a n t ¨ urk, E. T¨ uremen, T. S ¸ahin,
and C. Duman, “Endothelial dysfunction in young women
with polycystic ovary syndrome: relationship with insulin
resistance and low-grade chronic inﬂammation,” Journal of
Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp.
5592–5596, 2004.
[10] S. Benson, O. E. Janssen, S. Hahn et al., “Obesity, depression,
and chronic low-grade inﬂammation in women with polycys-
tic ovary syndrome,” Brain, Behavior, and Immunity, vol. 22,
no. 2, pp. 177–184, 2008.
[11] N. Boulman, Y. Levy, R. Leiba et al., “Increased C-reactive
protein levels in the polycystic ovary syndrome: a marker of
cardiovascular disease,” Journal of Clinical Endocrinology and
Metabolism, vol. 89, no. 5, pp. 2160–2165, 2004.
[12] A. N. Vgontzas, G. Trakada, E. O. Bixler et al., “Plasma
interleukin 6 levels are elevated in polycystic ovary syndrome
independently of obesity or sleep apnea,” Metabolism, vol. 55,
no. 8, pp. 1076–1082, 2006.
[13] J. Rouru, L. Anttila, P. Koskinen et al., “Serum leptin
concentrations in women with polycystic ovary syndrome,”
Journal of Clinical Endocrinology and Metabolism, vol. 82, no.
6, pp. 1697–1700, 1997.
[14] G. Gennarelli, J. Holte, L. Wide, C. Berne, and H. Lithell, “Is
there a role for leptin in the endocrine and metabolic aber-
rations of polycystic ovary syndrome?” Human Reproduction,
vol. 13, no. 3, pp. 535–541, 1998.
[15] H. S. Jacobs and G. S. Conway, “Leptin, polycystic ovaries and
polycysticovarysyndrome,”HumanReproductionUpdate,vol.
5, no. 2, pp. 166–171, 1999.
[16] B. Yildirim, N. Sabir, and B. Kaleli, “Relation of intra-
abdominal fat distributiontometabolicdisordersinnonobese
patients with polycystic ovary syndrome,” Fertility and Steril-
ity, vol. 79, no. 6, pp. 1358–1364, 2003.
[17] F. Orio Jr., S. Palomba, T. Cascella et al., “Adiponectin levels
in women with polycystic ovary syndrome,” Journal of Clinical
Endocrinology and Metabolism, vol. 88, no. 6, pp. 2619–2623,
2003.
[18] D. Panidis, A. Kourtis, D. Farmakiotis, T. Mouselech, D.
Rousso, and G. Koliakos, “Serum adiponectin levels in women
with polycystic ovary syndrome,” Human Reproduction, vol.
18, no. 9, pp. 1790–1796, 2003.
[19] A.M.Fulghesu,S.Angioni,E.Portogheseetal.,“Failureofthe
homeostatic model assessment calculation score for detecting
metabolic deterioration in young patients with polycystic
ovary syndrome,” Fertility and Sterility, vol. 86, no. 2, pp. 398–
404, 2006.
[ 2 0 ]M .K a r a d e n i z ,M .E r d o ˇ gan, S. Tamsel et al., “Oxidative stress
markersinyoungpatientswithpolycysticovarysyndrome,the
relationship between insulin resistances,” Experimental and
Clinical Endocrinology and Diabetes, vol. 116, no. 4, pp. 231–
235, 2008.
[21] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group, “Revised 2003 consensus on diagnostic
criteria and long-term health risks related to polycystic ovary
syndrome,” Human Reproduction, vol. 19, no. 1, pp. 41–47,
2004.
[22] National Diabetes Data Group, “Classiﬁcation and diagnosis
of diabetes mellitus and other categories of glucose intoler-
ance,” Diabetes, vol. 28, pp. 1039–1057, 1979.
[23] N. H. Jones, “Finding the area under the curve using jmp and
a trapezoidal rule,” SAS Institute, Cary, NC, USA, 1997.
[24] E. Carmina and R. A. Lobo, “Use of fasting blood to assess
the prevalence of insulin resistence in women with polycystic
ovariansyndrome,”FertilityandSterility,vol.82,pp.661–665,
2004.
[25] A. Lanzone, A. M. Fulghesu, F. Cucinelli, M. Ciampelli, A.
Caruso, and S. Mancuso, “Evidence of distinct rearrangement
of opioid tone in hyperinsulinemic patients with polycystic
ovarian syndrome: relationship with insulin and luteinising
hormone secretion,” Journal of Clinical Endocrinology &
Metabolism, vol. 80, pp. 3501–3506, 1995.
[26] G. Mantovani, A. Macci` o, S. Esu et al., “Medroxyprogesterone
acetate reduces the In vitro production of cytokines and sero-
tonin involved in anorexia/cachexia and emesis by peripheral
blood mononuclear cells of cancer patients,” European Journal
of Cancer Part A, vol. 33, no. 4, pp. 602–607, 1997.8 Mediators of Inﬂammation
[27] M. M. Bradford, “A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein dye binding,” Analytical Biochemistry, vol.
72, no. 1-2, pp. 248–254, 1976.
[28] F. Sanna, R. R. Bonatesta, B. Frongia et al., “Production
of inﬂammatory molecules in peripheral blood mononu-
clear cells from severely glucose-6-phosphate dehydrogenase-
deﬁcient subjects,” Journal of Vascular Research, vol. 44, no. 4,
pp. 253–263, 2007.
[29] R. R. Bonatesta, F. Sanna, S. Uda et al., “Inhibition of
cholesterol esteriﬁcation inﬂuences cytokine exspression in
lypopolisaccharide-activated P388D1 macrophages,” Ameri-
can Journal of Infectious Diseases, vol. 3, no. 3, pp. 151–158,
2007.
[30] S. Cook, M. Weitzman, P. Auinger, M. Nguyen, and W.
H. Dietz, “Prevalence of a metabolic syndrome phenotype
in adolescents: ﬁndings from the Third National Health
and Nutrition Examination Survey, 1988–1994,” Archives of
Pediatrics and Adolescent Medicine, vol. 157, no. 8, pp. 821–
827, 2003.
[31] E. Carmina, S. Bucchieri, A. Esposito et al., “Abdominal fat
quantity and distribution in women with polycystic ovary
syndrome and extent of its relation to insulin resistance,”
Journal of Clinical Endocrinology and Metabolism, vol. 92, no.
7, pp. 2500–2505, 2007.
[ 3 2 ]J .C .L o ,S .L .F e i g e n b a u m ,J .Y a n g ,A .R .P r e s s m a n ,J .V .
Selby,andA.S.Go,“Epidemiologyandadversecardiovascular
risk proﬁle of diagnosed polycystic ovary syndrome,” Journal
of Clinical Endocrinology and Metabolism,v o l .9 1 ,n o .4 ,p p .
1357–1363, 2006.
[33] E. Dahlgren, P. O. Janson, S. Johansson, L. Lapidus, and A.
Oden, “Polycystic ovary syndrome and risk for myocardial
infarction: evaluated from a risk factor model based on a
prospective population study of women,” Acta Obstetricia et
Gynecologica Scandinavica, vol. 71, no. 8, pp. 599–604, 1992.
[ 3 4 ] S .W i l d ,T .P i e r p o i n t ,H .J a c o b s ,a n dP .M c K e i g u e ,“ L o n g - t e r m
consequences of polycystic ovary syndrome: results of a 31
year follow-up study,” Human Fertility, vol. 3, no. 2, pp. 101–
105, 2000.
[35] N. Samy, M. Hashim, M. Sayed, and M. Said, “Clinical
signiﬁcance of inﬂammatory markers in polycystic ovary
syndrome: their relationship to insulin resistance and body
massindex,”DiseaseMarkers,vol.26,no.4,pp.163–170,2009.
[36] C. C. J. Kelly, H. Lyall, J. R. Petrie, G. W. Gould, J. M. C.
Connell, and N. Sattar, “Low grade chronic inﬂammation in
women with polycystic ovarian syndrome,” Journal of Clinical
Endocrinology and Metabolism, vol. 86, no. 6, pp. 2453–2455,
2001.
[37] V. Fenkci, S. Fenkci, M. Yilmazer, and M. Serteser, “Decreased
total antioxidant status and increased oxidative stress in
women with polycystic ovary syndrome may contribute to the
risk of cardiovascular disease,” Fertility and Sterility, vol. 80,
no. 1, pp. 123–127, 2003.
[38] B. Antuna-Puente, B. Feve, S. Fellahi, and J. P. Bastard,
“Adipokines: the missing link between insulin resistance and
obesity,” Diabetes and Metabolism, vol. 34, no. 1, pp. 2–11,
2008.
[39] J. P. Casas, T. Shah, A. D. Hingorani, J. Danesh, and M.
B. Pepys, “C-reactive protein and coronary heart disease: a
critical review,” Journal of Internal Medicine, vol. 264, no. 4,
pp. 295–314, 2008.
[40] L. Ib´ a˜ nez, A. M. Jaramillo, A. Ferrer, and F. de Zegher,
“High neutrophil count in girls and women with hyperinsuli-
naemic hyperandrogenism: normalization with metformin
and ﬂutamide overcomes the aggravation by oral contracep-
tion,” Human Reproduction, vol. 20, no. 9, pp. 2457–2462,
2005.
[41] S. Lee, F. Bacha, N. Gungor, and S. Arslanian, “Comparison of
diﬀerent deﬁnitions of pediatric metabolic syndrome: relation
to abdominal adiposity, insulin resistance, adiponectin, and
inﬂammatory biomarkers,” Journal of Pediatrics, vol. 152, no.
2, pp. 177–e3, 2008.
[ 4 2 ] E .C a r m i n a ,R .S .L e g r o ,K .S t a m e t s ,J .L o w e l l ,a n dR .A .L o b o ,
“Diﬀerence in body weight between American and Italian
women with polycystic ovary syndrome: inﬂuence of the diet,”
Human Reproduction, vol. 18, no. 11, pp. 2289–2293, 2003.
[43] E.Carmina,N.Napoli,R.A.Longo,G.B.Rini,andR.A.Lobo,
“Metabolic syndrome in polycystic ovary syndrome (PCOS):
lower prevalence in southern Italy than in the USA and the
inﬂuence of criteria for the diagnosis of PCOS,” European
Journal of Endocrinology, vol. 154, no. 1, pp. 141–145, 2006.
[44] A. O’Connor, N. Phelan, T. K. Tun, G. Boran, J. Gibney,
and H. M. Roche, “High-molecular-weight adiponectin is
selectively reduced in women with polycystic ovary syndrome
independent of body mass index and severity of insulin
resistance,” Journal of Clinical Endocrinology and Metabolism,
vol. 95, no. 3, pp. 1378–1385, 2010.
[45] A. Bideci, M. O. C ¸a m u r d a n ,E .Y e s ¸ilkaya, F. Demirel, and P.
Cinaz, “Serum ghrelin, leptin and resistin levels in adolescent
girlswithpolycysticovarysyndrome,”JournalofObstetricsand
Gynaecology Research, vol. 34, no. 4, pp. 578–584, 2008.
[46] T. Sathyapalan and S. L. Atkin, “Mediators of inﬂammation in
polycystic ovary syndrome in relation to adiposity,” Mediators
of Inﬂammation, vol. 2010, Article ID 758656, 5 pages, 2010.
[47] G. Garruti, R. Depalo, M. G. Vita et al., “Adipose tissue,
metabolic syndrome and polycystic ovary syndrome: from
pathophysiology to treatment,” Reproductive BioMedicine
Online, vol. 19, no. 4, pp. 552–563, 2009.
[48] A. F. Godoy-Matos, F. Vaisman, A. P. Pedrosa, M. L. F. Farias,
L. M. C. Mendonc ¸a, and M. F. M. C. Pinheiro, “Central-to-
peripheral fat ratio, but not peripheral body fat, is related to
insulin resistance and androgen markers in polycystic ovary
syndrome,” Gynecological Endocrinology, vol. 25, no. 12, pp.
793–798, 2009.
[49] A.V.Araya,A.Aguirre,C.Romero,C.Miranda,M.C.Molina,
and A. Ferreira, “Evaluation of tumor necrosis factor alpha
production in ex vivo short term cultured whole blood from
women with polycystic ovary syndrome,” European Cytokine
Network, vol. 13, no. 4, pp. 419–424, 2002.
[50] M.Y.Abeywardena,W.R.Leifert,K.E.Warnes,J.N.Varghese,
and R. J. Head, “Cardiovascular biology of interleukin-6,”
CurrentPharmaceuticalDesign, vol. 15, no. 15, pp. 1809–1821,
2009.
[51] R. Medzhitov, “Origin and physiological roles of inﬂamma-
tion,” Nature, vol. 454, no. 7203, pp. 428–435, 2008.
[52] R. R. S. Packard, A. H. Lichtman, and P. Libby, “Innate
and adaptive immunity in atherosclerosis,” Seminars in
Immunopathology, vol. 31, no. 1, pp. 5–22, 2009.
[53] N. M. Moutsopoulos and P. N. Madianos, “Low-grade
inﬂammation in chronic infectious diseases: paradigm of
periodontal infections,” Annals of the New York Academy of
Sciences, vol. 1088, pp. 251–264, 2006.
[54] C. J. Wiedermann, S. Kiechl, S. Dunzendorfer et al., “Asso-
ciation of endotoxemia with carotid atherosclerosis and
cardiovascular disease: prospective results from the Bruneck
Study,” Journal of the American College of Cardiology, vol. 34,
no. 7, pp. 1975–1981, 1999.